



February 23, 2015

Acura Pharmaceuticals to Host 2014 Financial Results Conference Call on March 3, 2015

PALATINE, IL -- (Marketwired) -- 02/23/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating [abuse deterrent drugs](#), today announced that the Company plans to report financial results for 2014 following the close of financial markets on Monday, March 2, 2015. The Company will host a conference call to discuss the results on Tuesday, March 3, 2015 at 8:30 a.m. ET.

To participate in the live conference call, please dial 888-468-2440 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 7932939.

A replay of the call will be available beginning March 4, 2015 and ending on March 24, 2015 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 7932939.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved Oxaydo™ (oxycodone HCl immediate release tablets) which incorporates the AVERSION Technology. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation, pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. The Company has a development pipeline of additional AVERSION Technology products containing other opioids.

Contact:
for Acura Investor Relations
[Email contact](#)
847-705-7709

for Acura Media Relations
[Email contact](#)
847-705-7709

Source: Acura Pharmaceuticals, Inc.

News Provided by Acquire Media